ArticleProceedings of the National Academy of Sciences of the United States of America2009
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 117 citations in OpenAlex.
- The regulation of COX-2, ABCA1, and ABCG1 by the lncRNA PACERR links the inflammatory response and cholesterol homeostasis.Cell reports · 2026Article
- Circulating oxylipins predict mortality in heart failure with preserved ejection fraction.ESC heart failure · 2025Observational
- Oxylipins are Associated With Poor Right Ventricular to Pulmonary Artery Coupling and Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.The American journal of cardiology · 2025Article
- Prostaglandins and the Cardiovascular System.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β-Adrenergic Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications.EXCLI journal · 2025Review
- Early- to mid-gestational testosterone excess leads to adverse cardiac outcomes in postpartum sheep.American journal of physiology. Heart and circulatory physiology · 2024Article
- Prostanoids in Cardiac and Vascular Remodeling.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Synthesis, Characterization, DFT, and In Silico Investigation of Two Newly Synthesized β-Diketone Derivatives as Potent COX-2 Inhibitors.Bioengineering (Basel, Switzerland) · 2023Article
- Cyclooxygenase-2 in adipose tissue macrophages limits adipose tissue dysfunction in obese mice.The Journal of clinical investigation · 2022Article
- Pharmacological modulation of prostaglandin EPhysiological reports · 2022Article
- Sexual dimorphism in testosterone programming of cardiomyocyte development in sheep.American journal of physiology. Heart and circulatory physiology · 2022Article
- Article
- Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury.Kidney international · 2022Article
- The protective effects of naproxen against interleukin-1β (IL-1β)- induced damage in human umbilical vein endothelial cells (HUVECs).Bioengineered · 2021Article
- Spaceflight Modulates the Expression of Key Oxidative Stress and Cell Cycle Related Genes in Heart.International journal of molecular sciences · 2021Article
- COX2 regulates senescence secretome composition and senescence surveillance through PGECell reports · 2021Article
- The zebrafishProceedings of the National Academy of Sciences of the United States of America · 2021Article
- A Long-Term Pilot Study on Sex and Spinal Cord Injury Shows Sexual Dimorphism in Functional Recovery and Cardio-Metabolic Responses.Scientific reports · 2020Article
- Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?International journal of molecular sciences · 2019Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
Nonsteroidal anti-inflammatory drugs selective for inhibition of COX-2 increase heart failure and elevate blood pressure. The COX-2 gene was floxed and crossed into merCremer mice under the alpha-myosin heavy-chain promoter. Tamoxifen induced selective deletion of COX-2 in cardiomyocytes depressed cardiac output, and resulted in weight loss, diminished exercise tolerance, and enhanced susceptibility to induced arrhythmogenesis. The cardiac dysfunction subsequent to pressure overload recovered progressively in the knockouts coincident with increasing cardiomyocyte hypertrophy and interstitial and perivascular fibrosis. Inhibition of COX-2 in cardiomyocytes may contribute to heart failure in patients receiving nonsteroidal anti-inflammatory drugs specific for inhibition of COX-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.